Amneal Pharmaceuticals (NASDAQ:AMRX) Issues FY 2025 Earnings Guidance

Key Points

• Amneal Pharmaceuticals has issued FY 2025 earnings guidance with EPS estimated between 0.700-0.750, versus a consensus estimate of 0.705.
• The company expects revenue in the range of $3.0 billion to $3.1 billion, matching the consensus revenue estimate of $3.0 billion.
• After recent updates, analysts have generally rated Amneal Pharmaceuticals with a consensus rating of “Buy”, with a target price of $11.60.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided EPS guidance of 0.700-0.750 for the period, compared to the consensus EPS estimate of 0.705. The company issued revenue guidance of $3.0 billion-$3.1 billion, compared to the consensus revenue estimate of $3.0 billion.

Amneal Pharmaceuticals Price Performance

AMRX traded up $0.29 during trading hours on Tuesday, hitting $8.25. 1,580,700 shares of the stock were exchanged, compared to its average volume of 1,673,092. The stock has a 50-day simple moving average of $7.95 and a 200-day simple moving average of $7.96. Amneal Pharmaceuticals has a 12 month low of $6.59 and a 12 month high of $9.48. The stock has a market cap of $2.58 billion, a price-to-earnings ratio of -206.07 and a beta of 1.11.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported $0.23 earnings per share for the quarter, topping the consensus estimate of $0.17 by $0.06. Amneal Pharmaceuticals had a negative return on equity of 188.26% and a negative net margin of 0.46%. Sell-side analysts expect that Amneal Pharmaceuticals will post 0.53 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on AMRX shares. Wall Street Zen lowered Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, May 13th. The Goldman Sachs Group started coverage on Amneal Pharmaceuticals in a research report on Friday, June 6th. They issued a "buy" rating and a $12.00 price target for the company. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, Amneal Pharmaceuticals has a consensus rating of "Buy" and a consensus price target of $11.60.

Hedge Funds Weigh In On Amneal Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Dynamic Technology Lab Private Ltd acquired a new position in shares of Amneal Pharmaceuticals during the first quarter valued at $244,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Amneal Pharmaceuticals by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 94,638 shares of the company's stock valued at $793,000 after acquiring an additional 4,178 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Amneal Pharmaceuticals by 5.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 334,956 shares of the company's stock valued at $2,807,000 after acquiring an additional 16,536 shares during the period. Finally, Millennium Management LLC lifted its stake in shares of Amneal Pharmaceuticals by 32.6% during the first quarter. Millennium Management LLC now owns 2,087,398 shares of the company's stock valued at $17,492,000 after acquiring an additional 512,842 shares during the period. Institutional investors and hedge funds own 31.82% of the company's stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.